Basu A. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):163-5. doi: 10.1586/erp.13.8.
Basu A. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):163-5. doi: 10.1586/erp.13.8.